Pricing Log in Create free account
Saturday 17 October 2026 Export TRVN’s income statement to Excel — free account

Trevena, Inc.

TRVN Healthcare Biotechnology

Revenue growth for three consecutive years, operating cash flow growth for three.

0.00 0.07 −100.00%
Market cap
$1.8M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
n/a
Altman Z
−22.13
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.35%

Capital & Financial Ratios $m

Market Cap 1.81
Revenue 0.55
Net Income (34.04)
Free Cash Flow (27.09)
Net Debt 19.13
Current Ratio 2.42 (at or above 1.5: strong)
Debt/Equity (1.41) (negative: negative equity)
P/E ratio 0.00
Fwd P/E (0.07) (negative: loss-making)
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 60.50% (at or above 15%: strong)
Next Y EPS Growth 36.40% (at or above 15%: strong)
Next Y revenue growth (79.90%) (below 0%: weak)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 35.0×, against a ten-year median of 25.3×; over the ten years it ranged from −10.2× in 2022 to 206× in 2021.
EV/Sales against its own 10 years 59.66%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2021 2022 2023 Q'24
Cash 67 38 33 14
Receivables — — — —
Inventory 2 1 — —
Other — — — —
71 41 35 15
2021 2022 2023 Q'24
Payables 5 2 2 1
ST’ Debt — — — 1
Other — — — —
9 9 8 6

Compound Annual Growth %

10y 5y 3y
Sales — (11.43%) 0.60%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 0 — —
’23 0 3 0 — 3
’22 0 — — 0 —
’21 0 0 0 0 1
’20 — — 3 0 3
’19 — — — 0 0
’18 — 3 3 0 6
Fiscal quarters ending in the months shown.
value withheld pending a data check

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (7) (5) — —
’23 (11) (7) (9) (6) (33)
’22 (18) (12) (11) (11) (51)
’21 (14) (12) (11) (13) (50)
’20 (6) (5) (3) (7) (21)
’19 (8) (3) (6) (7) (24)
’18 (10) (5) (4) (6) (25)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (7) (5) — —
’23 (11) (7) (9) (6) (33)
’22 (18) (12) (11) (11) (52)
’21 (14) (12) (11) (13) (50)
’20 (6) (5) (3) (7) (21)
’19 (8) (3) (6) (7) (24)
’18 (11) (5) (4) (5) (26)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (9.00) (5.75) (5.79) — —
’23 (20.25) (17.25) (14.25) (26.50) (79.00)
’22 (62.50) (56.25) (56.25) (18.25) (189.75)
’21 (37.50) (56.25) (50.00) (50.00) (200.00)
’20 (37.50) (37.50) (25.00) (50.00) (143.75)
’19 (37.50) (31.25) (56.25) (43.75) (168.75)
’18 (87.50) (81.25) (37.50) (62.50) (262.50)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Trend 2024e 2025e 2026e
Price, $
Price, $ Low — — 2,350.00 843.75 238.94 268.13 287.50 350.00 32.50 12.71

Analyst estimates 2024–2026

Powerpack
High — — 6,568.56 5,000.00 2,236.44 1,250.00 2,300.00 1,937.50 402.19 82.00
People
People Employees — — 72 51 29 24 25 43 35 23
Revenue/emp, $m — — 0.05 0.00 0.20 0.00 0.12 0.01 (0.01) 0.14
Income, $m
Income, $m Revenue — — 4 — 6 0 3 1 — 3
Gross margin, % — — 100.00 0.00 100.00 100.00 94.07 (68.25) 822.01 46.56
EBT — — (103) (72) (30) (25) (29) (52) (54) (40)
EBT margin, % — — (2,746.51) 0.00 (524.06) (80,229.03) (947.18) (9,098.41) 12,839.71 (1,289.25)
Net income — — (103) (72) (31) (25) (29) (52) (54) (40)
Depreciation — — 2 1 0 0 0 0 0 0
Per share, $
Per share, $ Revenue — — 44.75 0.00 48.70 0.21 15.03 2.17 (1.48) 6.13
Earnings — — (1,231.25) (756.25) (262.50) (168.75) (143.75) (200.00) (189.75) (79.00)
Cash flow — — (1,092.53) (749.26) (215.59) (161.33) (104.77) (192.18) (181.96) (64.85)
Capex — — (7.22) (36.75) (1.44) 0.00 (0.13) (0.06) (0.10) (0.08)
Free cash flow — — (1,099.75) (786.01) (217.03) (161.33) (104.90) (192.24) (182.06) (64.93)
Book value — — 937.72 364.17 352.81 205.03 509.64 247.43 55.14 (15.03)
Shares, m — — 0 0 0 0 0 0 0 1
Valuation, ×
Valuation, × P/E — — 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — 42.95 — 4.16 13.38 81.97 167.71 0.00 3.01
P/B — — 4.10 — 0.76 2.56 2.62 1.47 0.69 0.00
EV/Sales — — 30.64 — (1.64) 9.39 51.48 62.21 31.43 2.63
EV/FCF — — (2.49) — 0.49 (2.27) (8.00) (0.70) 0.26 (0.25)
Cash, $m
Cash, $m Operating cash flow — — (92) (71) (25) (24) (21) (50) (51) (33)
Capex — — (1) (3) 0 — 0 0 0 0
Free cash flow — — (92) (75) (26) (24) (21) (50) (52) (33)
Balance, $m
Balance, $m Working capital — — 90 49 45 28 102 62 32 28
Total debt — — 18 28 17 13 7 6 13 31
Net debt — — (92) (38) (44) (23) (102) (61) (25) (2)
Shareholders’ equity — — 79 35 42 30 104 65 16 (8)
Returns, %
Returns, % ROA — — (71.03) (76.71) (44.13) (43.72) (33.62) (49.64) (83.34) (90.25)
ROIC — — 0.00 0.00 0.00 (233.52) (1,043.50) (808.30) 0.00 0.00
ROE — — (92.91) (126.95) (80.84) (69.47) (43.79) (61.16) (133.79) (1,014.57)
Negative figures in brackets.
value withheld pending a data check

All 10 years →

Fiscal years to Dec 2023 · latest quarter Sep 2024

Charts ten years each

Trevena, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CLSDQ Clearside Biomedical, Inc. $2.2M — (loss-making) — (loss-making) −80.64% (below 0%: shrinking) n/m +8.15% (above 0%: growing) 100.00% (3,502.49%) Compare
BRTX Biorestorative Therapies, Inc. $2.0M — (loss-making) — (loss-making) −7.20% (below 0%: shrinking) n/m −35.26% (below 0%: shrinking) 68.10% (14,593.53%) Compare
PPBT Purple Biotech Ltd. Sponsored ADR $2.0M — (loss-making) — (loss-making) — n/m −62.10% (below 0%: shrinking) 0.00% 0.00% Compare
OGEN Oragenics, Inc. $2.0M 0.4× — (loss-making) −75.33% (below 0%: shrinking) n/m −66.37% (below 0%: shrinking) 100.00% 0.00% Compare
SILO Silo Pharma, Inc. $1.9M — (loss-making) 18.4× 0.00% n/m +39.17% (above 0%: growing) (15.00%) 0.00% Compare
GNPX GENPREX $1.9M 0.0× — — n/m −32.98% (below 0%: shrinking) 0.00% 0.00% Compare
TRVN Trevena, Inc. $1.8M — (loss-making) — (loss-making) +57.22% (above 0%: growing) n/m +49.55% (above 0%: growing) 59.72% (1,970.67%)
NEXI NexImmune, Inc. $1.6M — (loss-making) — — n/m +66.38% (above 0%: growing) 0.00% 0.00% Compare
ITRMF Iterum Therapeutics PLC $1.6M — (loss-making) — (loss-making) +110.81% (above 0%: growing) n/m −179.15% (below 0%: shrinking) 94.87% (1,982.31%) Compare
Median of peers $1.9M — — −7.20% — −34.12% 34.05% 0.00%

All 614 Biotechnology stocks →

Trevena, Inc. (TRVN) key facts

  • Trevena, Inc. (TRVN) is a Biotechnology company in the Healthcare sector.
  • Return on equity was −1,014.6% and debt-to-equity -1.41.
  • Its Altman Z-score is −22.13 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.

Trevena, Inc. (TRVN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/TRVN · Data as of Sep 30, 2024 · For information only; not investment advice. · © 2026 stockrow.com